CD44 and ovarian carcinoma: Work conducted by Li et al. demonstrated that the combined utilization of osimertinib alongside CQ significantly reduced the expressions of ALDH1A1, SOX2 proteins, and the CD133/CD44 positive cell population in osimertinib-resistant cells, highlighting a critical role of autophagy in mediating the stemness of ovarian cancer cells [41].